Buy the GCP R3 course & get a FREE eBook— your complete ICH-GCP R3 reference guide. Book Now →

  • AI ClinicalAI ClinicalNewRight Arrow
  • Clinical PracticeClinical PracticeRight Arrow
  • PharmacovigilancePharmacovigilanceRight Arrow
  • ManufacturingManufacturingRight Arrow
  • Laboratory PracticeLaboratory PracticeRight Arrow
  • DistributionDistributionRight Arrow
  • Medical DevicesMedical DevicesRight Arrow
  • Regulatory AffairsRegulatory AffairsRight Arrow
  • Research ComplianceResearch ComplianceRight Arrow
  • Health & SafetyHealth & SafetyRight Arrow
  • Quality AssuranceQuality AssuranceRight Arrow
  • All Bundles
  • Clinical Trials Development
  • GCP & GxP Standards
  • Pharmacovigilance
  • Role Based
  • Distribution
  • Medical Devices
  • Medical Writing
  • AI Clinical
View all 21 learning paths
  • Preclinical & Laboratory Foundations Learning Path
  • Phase I – First-in-Human Trials Learning Path
  • Phase II & III – Efficacy & Pivotal Trials Learning Path
  • Clinical Trials Foundation PathNew
  • Regulatory Submission & Approval
Preclinical & Laboratory Foundations Learning Path - courses at £199

About

Sterilisation and sterile barrier packaging validation are essential to ensuring that medical devices are delivered sterile, remain protected throughout storage and transportation, and perform safely at the point of use. Effective validation combines microbiological principles, robust process controls, packaging science, and regulatory compliance to maintain product sterility throughout its lifecycle.
This Medical Device Sterilisation and Sterile Barrier Packaging Validation Training Course & Certification provides comprehensive knowledge of microbiology fundamentals, sterilisation method selection, ethylene oxide, radiation, and moist heat sterilisation validation, routine process control, sterile barrier system design, packaging process validation, integrity testing, ageing studies, distribution validation, supplier management, requalification, lifecycle control, and compliance with ISO 11135, ISO 11137, ISO 17665, and ISO 11607. Upon successful completion, learners receive a certification demonstrating their understanding of sterilisation validation and sterile barrier packaging best practices for medical devices.

Who Should Enrol?

  • Medical Device Design and Manufacturing Engineers
  • Sterilisation and Packaging Validation Professionals
  • Quality Assurance and Quality Management Professionals
  • Regulatory Affairs and Compliance Professionals
  • Validation and Process Engineers
  • Packaging Engineers and Sterile Barrier System Specialists
  • Microbiology and Laboratory Professionals
  • Anyone involved in the design, validation, manufacture, or regulatory compliance of sterile medical devices
📢 Every purchase also includes our FREE companion Sterilisation and Sterile Barrier Packaging Validation eBook, designed to help you apply principles in real-world clinical trial settings.

What you will learn

Understand the principles of medical device sterilisation, microbiology, sterile barrier systems, and the regulatory and quality requirements governing sterile medical devices.

Learn how to select appropriate sterilisation methods, validate ethylene oxide, radiation, and moist heat sterilisation processes, and establish routine process controls.

Develop knowledge of sterile barrier system design, packaging process validation, integrity testing, accelerated and real-time ageing studies, and distribution simulation.

Gain practical understanding of requalification, supplier management, lifecycle monitoring, documentation, and compliance with ISO 11135, ISO 11137, ISO 17665, and ISO 11607 requirements.

Course Syllabus

  1. The world of microorganisms
  2. Vegetative cells versus spores
  3. Bacterial endospores — the worst case
  4. Where contamination comes from
  5. How contamination reaches a device
  6. Controlling bioburden before sterilisation
  7. Bioburden defined
  8. Why bioburden matters
  9. Determining bioburden
  10. Recovery efficiency
  11. Bioburden variability and trending
  12. Microbial death is logarithmic
  13. The D-value
  14. From survivors to the SAL
  15. The Sterility Assurance Level
  16. Why 10^-6 for terminal sterilisation
  17. Sterility is a probability, not pass/fail
  18. What 'sterile' means operationally
  19. Overkill and bioburden-based approaches
  20. Exposure sets the SAL
  21. What sterility testing is
  22. The sterility test method in outline
  23. The statistics of sterility testing
  24. Why testing cannot validate a process
  25. Destructive cost and sampling limits
  26. Process control assures sterility
  27. Parametric release
  28. Biological indicators
  29. Using biological indicators in validation
  30. Physical versus biological monitoring
  31. Process challenge devices
  32. The microbiological methods map
  33. Characterising a sterilising agent
  34. Four decontamination processes
  35. Cleaning
  36. Disinfection and its levels
  37. Sterilisation
  38. Aseptic processing
  39. Terminal sterilisation versus aseptic
  40. Do not conflate the processes
  41. Cleaning validation is a different course
  42. The regulatory foundations
  43. EU MDR — sterile devices
  44. MDR Annex I in practice
  45. The FDA framework
  46. Standard, regulation, guidance — again
  47. The sterility and microbiology standards map
  48. Risk management threads through
  49. Evidence and documentation expectations
  50. Case: NeoCath bioburden strategy
  51. Case: NeoCath SAL rationale
  52. Common failures — sterility and microbiology
  53. From bioburden to SAL — the through-line
  54. Which microbiological standard when
  55. The half-cycle concept — a preview
  56. Sterility depends on the sterile barrier
  57. Decontamination terminology precision

  1. The sterilisation toolbox
  2. Terminal sterilisation, in principle
  3. Ethylene oxide — principle
  4. Ethylene oxide — what validation controls
  5. Ethylene oxide — residuals matter
  6. Radiation sterilisation — overview
  7. Gamma, E-beam and X-ray compared
  8. Radiation — dose sets lethality
  9. Moist heat sterilisation
  10. Moist heat — where it fits
  11. Dry heat and other approaches
  12. Alternative sterilising agents
  13. The methods at a glance
  14. Strengths and limits by modality
  15. No single method fits all
  16. Selection is a risk-based decision
  17. The inputs to selection
  18. Input: materials and compatibility
  19. Input: polymer and radiation effects
  20. Input: geometry, lumens and surfaces
  21. Input: packaging compatibility
  22. Input: residuals and toxicology
  23. Input: bioburden and density
  24. Input: throughput and supply continuity
  25. Input: regulatory and market factors
  26. Sustainability and EO reduction
  27. The method-selection decision tree
  28. Walking the tree — NeoCath Secure
  29. The method-selection worksheet
  30. Documenting the rationale
  31. A dual-modality strategy
  32. Why define products before validating
  33. Product families
  34. Family grouping principles
  35. The product family rationale
  36. Process categories
  37. Families versus categories
  38. Worst-case configuration
  39. Why worst-case governs validation
  40. Worst case for ethylene oxide
  41. Worst case for radiation
  42. Worst case for moist heat
  43. Master product and equivalence
  44. Selecting the worst case — worksheet
  45. Bracketing and family efficiency
  46. The validation master plan
  47. Selection feeds the validation plan
  48. A change of method is a major change
  49. From selection to qualification
  50. Method selection recap map

  1. What ethylene oxide does to microorganisms
  2. EO is hazardous — a control-level discipline
  3. The EO process at a control level
  4. The variables that determine EO lethality
  5. Why humidity is decisive in EO
  6. Aeration and residual removal — purpose
  7. Is EO the right method? Rule one applies
  8. EO positioned against other modalities
  9. The effective EO standard — and the pending revision
  10. How ISO 11135 relates to the general standard
  11. Validation is a lifecycle, not an event
  12. Building the validation strategy
  13. Who does what: manufacturer and contract steriliser
  14. The sterilisation process specification
  15. Risk management drives the strategy
  16. Product families group like with like
  17. Defining the worst-case configuration
  18. Bioburden informs the family and the challenge
  19. The internal process challenge rationale
  20. Preconditioning as a controlled parameter
  21. Conditioning and dwell inside the chamber
  22. Gas exposure parameters — what is controlled
  23. Temperature and humidity distribution in the chamber
  24. Aeration as a validated parameter
  25. Qualification in three stages: IQ, OQ, PQ
  26. Installation qualification — scope
  27. IQ — calibration and traceability
  28. Operational qualification — scope
  29. OQ — distribution studies characterise the chamber
  30. OQ — defining parameters and tolerances
  31. Performance qualification — the whole point
  32. Microbiological performance qualification
  33. Physical performance qualification
  34. How many runs, and why replicates matter
  35. Linking OQ and PQ to the worst case
  36. Sterility is a probability, expressed as SAL
  37. D-value and microbial resistance
  38. Biological indicators for EO
  39. Selecting the biological indicator
  40. Process challenge devices — internal and external
  41. Placing and validating the PCD
  42. The half-cycle (overkill) approach — logic
  43. Running the half-cycle method
  44. Demonstrating the SAL from overkill
  45. The bioburden-based approach as an alternative
  46. Combining biological and bioburden evidence
  47. PQ sterility testing is process definition — not release
  48. Fraction-negative and sub-lethal reasoning
  49. Physical process challenges — overview
  50. Load configuration as a worst-case control
  51. Physical parameters monitored during the cycle
  52. Why EO residuals matter
  53. ISO 10993-7 — the residuals principle
  54. Where EO and ECH residuals come from
  55. Determining residuals
  56. Aeration validated against residual limits
  57. Contact category drives the acceptable residual
  58. Material compatibility with EO
  59. Functional testing after EO exposure
  60. Packaging compatibility with EO
  61. Common EO validation failures
  62. From validation to routine control
  63. Change and requalification — the principle

  1. Radiation sterilisation — dose is the lethal agent
  2. Gamma radiation (cobalt-60)
  3. Electron beam (E-beam)
  4. X-ray sterilisation
  5. Comparing the radiation sources
  6. Why no biological indicator for routine release
  7. Induced radioactivity — a validated non-issue
  8. The current radiation standard
  9. The radiation standards map
  10. A short timeline of radiation sterilisation standards
  11. Is radiation the right method? Rule one applies
  12. Establishing the sterilisation dose
  13. Bioburden is the foundation of dose setting
  14. Dose-setting methods — an overview
  15. Method 1 in outline
  16. Method 2 in outline
  17. The VDmax dose-substantiation method
  18. The verification dose experiment
  19. Selecting the sterilisation dose and SAL
  20. The dose window: minimum and maximum
  21. Dose uniformity: the min-to-max ratio
  22. Dosimetry fundamentals
  23. Dosimeter systems and calibration
  24. Dose mapping
  25. Qualifying the irradiator (IQ/OQ)
  26. Performance qualification — product dose mapping
  27. Routine dosimetric control and release
  28. Dose audit and requalification
  29. Material effects of radiation
  30. Which polymers tolerate radiation
  31. Functional testing after the maximum dose
  32. Post-irradiation ageing effects
  33. Moist heat sterilisation — saturated steam
  34. The current moist-heat standard
  35. Saturated steam and steam quality
  36. Air removal and cycle types
  37. F0 — accumulated lethality
  38. D-value, z-value and lethality
  39. Heat penetration versus distribution
  40. Moist-heat load families
  41. Developing the moist-heat process
  42. Moist-heat installation qualification
  43. Moist-heat operational qualification
  44. Moist-heat performance qualification
  45. Biological indicators for moist heat
  46. Overkill and bioburden approaches for moist heat
  47. Equilibration and holding time
  48. Drying and load dryness
  49. Routine control and release for moist heat
  50. Requalification for moist heat
  51. When moist heat suits — and when it does not
  52. Positioning the three modalities
  53. Why NeoCath is not moist-heat suitable
  54. Alternative sterilisation methods in brief
  55. Physical challenges in radiation
  56. Physical challenges in moist heat
  57. Common radiation validation failures
  58. Common moist-heat validation failures
  59. Dose-setting and F0 pitfalls
  60. Sterility testing still cannot validate — rule two
  61. Requalification and change for both modalities
  62. Selecting between radiation and moist heat
  63. Release basis across the methods
  64. Evidence for audit and submission
  65. Integrating sterilisation with packaging and shelf life

  1. The validated state - and how it decays
  2. Validation is a lifecycle - discipline rule 6
  3. Sterility testing does not control the process - rule 2
  4. Three activities that maintain validation
  5. Outputs of PQ become the routine control basis
  6. Routine monitoring - the common pattern
  7. EO - routine monitoring parameters
  8. Radiation - routine monitoring parameters
  9. Moist heat - routine monitoring parameters
  10. Physical parameters versus biological monitoring
  11. Biological indicators and process challenge devices
  12. Alert and action limits, and trending
  13. Product release - what it means
  14. Release criteria - what is reviewed
  15. Parametric release - definition
  16. Parametric versus microbiological release
  17. Conditions for parametric release
  18. Radiation dosimetric release
  19. The batch record and release documentation
  20. Why requalify - confirming continued validity
  21. Requalification triggers
  22. Requalification cadence
  23. Requalification versus revalidation
  24. Radiation - the periodic dose audit
  25. EO and moist-heat requalification
  26. Change management - the discipline
  27. What counts as a change?
  28. Assessing a change - the impact assessment
  29. Proportional revalidation - the core principle
  30. Worked examples of proportional response
  31. Changing the sterilisation method - a fundamental change
  32. Deviations - definition and importance
  33. Handling a deviation - the workflow
  34. Root cause, CAPA and trending
  35. Contract sterilisers - why they are used
  36. Responsibility remains with the manufacturer
  37. Quality and technical agreements - purpose
  38. What a quality agreement should cover
  39. What a technical agreement should cover
  40. Qualifying and auditing the contract steriliser
  41. The supplier relationship - many touchpoints
  42. Calibration and instrument control
  43. Load configuration and its control
  44. Data integrity of routine records
  45. Alarms, interlocks and aborted cycles
  46. Reprocessing - when and how
  47. The legitimate roles of the sterility test
  48. Periodic product and process review
  49. Requalification and change documentation
  50. Onboarding a new contract steriliser
  51. Second-source strategy and supply continuity
  52. Deviation, nonconformance and out-of-specification
  53. Batch disposition options
  54. Audit and inspection readiness
  55. Common failures in routine control and supplier management
  56. Templates for routine control and change

  1. Why packaging matters for a sterile device
  2. Three terms with precise meanings
  3. The sterile barrier system, defined
  4. Protective packaging, defined
  5. The packaging system - the whole
  6. Preformed sterile barrier systems and forming
  7. Rule 5 - maintain sterility to the point of use
  8. Rule 3 - one integrity test is not enough
  9. ISO 11607 - Part 1 and Part 2
  10. What ISO 11607-1 covers
  11. The 2023 amendment - application of risk management
  12. Three validations kept distinct - rule 4
  13. Designing a sterile barrier system - the flow
  14. Design inputs for a sterile barrier system
  15. General requirements for an SBS
  16. The microbial barrier requirement
  17. Demonstrating the microbial barrier
  18. Compatibility with the sterilisation method
  19. Compatibility - EO and low-temperature methods
  20. Compatibility - radiation
  21. Compatibility - moist heat
  22. Packaging must not adversely affect the device
  23. Selecting sterile barrier materials
  24. Common sterile barrier materials
  25. Porous versus non-porous materials
  26. Material qualification requirements
  27. Specifying and controlling materials
  28. Biocompatibility of device-contacting packaging
  29. Suitability is a strategy - rule 3 in full
  30. From design to the forming and sealing process
  31. Integrity of the sterile barrier system
  32. Strength of seals and materials
  33. Information and labelling supplied with the package
  34. Symbols and standardised labelling
  35. Marking and printing without harming the barrier
  36. Aseptic presentation as a design input
  37. Designing for aseptic presentation
  38. Applying risk management to packaging
  39. Packaging hazards to design against
  40. Verifying and validating the design
  41. Choosing a package format
  42. Reusable rigid sterilisation container systems
  43. The conditions the package must survive
  44. The standards that govern the package
  45. MDR requirements for sterile packaging
  46. FDA recognition of packaging standards
  47. Design supports the shelf-life claim
  48. Integrating packaging with the wider evidence
  49. The packaging design file and traceability
  50. Validate the packaging system as a whole
  51. Common sterile barrier design failures
  52. Templates for sterile barrier design
  53. Bridge to ISO 11607-2 and the modules ahead
  54. Prototyping and design iteration
  55. Sustainability and supply in material choices

  1. Where Module 7 sits - from design to process
  2. What ISO 11607-2 requires
  3. Amendment 1:2023 - risk management applied
  4. Rule 4 - three validations, kept distinct
  5. Rule 3 - one integrity test is not proof
  6. Three process families to validate
  7. Design outputs become validation inputs
  8. The validation lifecycle: IQ, OQ, PQ
  9. Installation qualification (IQ)
  10. Operational qualification (OQ)
  11. Performance qualification (PQ)
  12. Worst-case and challenge conditions
  13. The packaging validation master plan
  14. Who owns packaging process validation
  15. Forming the thermoformed tray
  16. Forming critical process parameters
  17. Assembly process validation
  18. Manual versus automated processes
  19. Operators, training and process control
  20. How a heat seal forms
  21. The three critical process parameters
  22. What a seal process window is
  23. Establishing the window
  24. The seal window as temperature by pressure - NeoCath (SC-03)
  25. Reading the window: too cold and too hot
  26. Seal quality attributes
  27. Monitoring the seal in production
  28. Integrity versus strength - two questions
  29. A catalogue of test methods
  30. Dye penetration testing
  31. Bubble emission testing
  32. Vacuum decay testing
  33. Seal strength and peel testing
  34. Burst and creep testing
  35. Visual inspection and its limits
  36. Destructive versus non-destructive tests
  37. Selecting a method by purpose
  38. Whole-package versus seal-specific tests
  39. Gross versus fine leaks
  40. Sensitivity and detection limits
  41. Test methods must themselves be suitable
  42. Confirm the current edition before use
  43. ASTM and ISTA - roles
  44. Sample size and statistical confidence
  45. Interpreting a pass
  46. Interpreting a fail
  47. Distinguishing a failure from a test artefact
  48. Trend analysis on seal data
  49. Seal process capability
  50. Rule 3 as a hierarchy of evidence
  51. The packaging test method matrix (T016)
  52. Linking process validation to design inputs
  53. Environmental control during packaging
  54. Handling and in-plant transport
  55. Combining parameter and test evidence
  56. Documenting the validated state
  57. Peelability and aseptic presentation
  58. Change and revalidation - a preview
  59. Risk management runs through it all
  60. Common packaging validation failures
  61. Bridge to Module 8
  62. Seal width and uniformity
  63. Physical integrity and the microbial barrier
  64. Correlating non-destructive to destructive tests
  65. Frequency of routine seal testing
  66. Handling deviations during validation
  67. Data integrity of test records
  68. How many PQ lots and runs

  1. Where Module 8 sits - from made to maintained
  2. Shelf life and the sterility claim
  3. Rule 5 - maintain sterility to the point of use
  4. What ages a package
  5. A claim needs evidence, not assertion
  6. Two ageing approaches
  7. Accelerated ageing is a prediction
  8. The Arrhenius basis of accelerated ageing
  9. Choosing accelerated conditions
  10. Time-zero and ageing timepoints
  11. What is tested at each pull
  12. Limits of accelerated ageing
  13. Real-time ageing confirms
  14. Prediction is not proof
  15. Planning both studies together (T017)
  16. The hazards of distribution
  17. Distribution simulation
  18. Environmental conditioning
  19. The distribution test sequence
  20. Test after ageing and distribution
  21. Correlating simulation to real distribution
  22. Integrating the evidence
  23. Four evidence streams, one claim
  24. The integrated shelf-life evidence matrix (T019)
  25. Sequence: sterilise, then age
  26. Device performance over shelf life
  27. Distinct disciplines, integrated conclusions
  28. Consistency across the streams
  29. Bracketing and product families
  30. Preparing evidence for audit and submission
  31. EU technical documentation and the MDR
  32. FDA submissions and recognised standards
  33. What auditors and reviewers look for
  34. Traceability and retrieval
  35. The evidence package structure
  36. Data integrity and honest declaration
  37. Post-market data feeds the claim
  38. Validation is a lifecycle
  39. Types of change to assess
  40. The change assessment
  41. Proportional revalidation
  42. Revalidation triggers
  43. Sterile barrier and protective packaging over life
  44. Defining the storage conditions
  45. Replicates and sample size in ageing
  46. Interpreting an ageing failure
  47. Protective packaging in transit
  48. Unit-level and shipping-level testing
  49. Pressure changes in air transport
  50. Sterility maintenance evidence
  51. Reconciling accelerated and real-time results
  52. Records retention
  53. Handling reviewer and auditor questions
  54. Assessing supplier changes
  55. Documenting the change assessment (T020)
  56. Periodic requalification over time
  57. Ageing chamber control
  58. Aseptic presentation at the point of use
  59. Consistency of labelling and claim
  60. Common failures in shelf life and lifecycle

  1. 📘 Bonus: Sterilisation and Sterile Barrier Packaging Validation eBook (Free with purchase)

Our Certified Customers

novartis
NHS
takeda
roche
baxter

Learner Rating & Reviews

4.7
★★★★★★
Average Rating
536 global ratings
★★★★★
87.0%
★★★★★
5.0%
★★★★★
3.0%
★★★★★
3.0%
★★★★★
2.0%
RC

Working with Whitehall training for the last two years of partnership has been a very successful experience – I have fast access to all the GCP course...

SM

I have finalised the demo for the ICH-GCP E6 R3 refresher course. Overall, I liked the content and the interface. I also want to thank Whitehall Train...

Recommended Courses

Essentials of EU MDRBest Seller

Essentials of EU MDR

Professional
£493 hrs3 points
Risk Management for Medical Devices ISO 14971:2019

Risk Management for Medical Devices ISO 14971:2019

Intermediate
£393 hrs2 points
QMS Auditing & Inspection Readiness – ISO 13485:2016 Internal Auditor

QMS Auditing & Inspection Readiness – ISO 13485:2016 Internal Auditor

Intermediate
£393 hrs2 points
Advanced Medical Device Lifecycle, Clinical Investigations & Risk Management

Advanced Medical Device Lifecycle, Clinical Investigations & Risk Management

Intermediate
£393 hrs2 points
Agile Medical Device Software Development

Agile Medical Device Software Development

Intermediate
£393 hrs3 points